Prostate cancer is the most common type of cancer, and the ability to distinguish indolent from aggressive tumours remains one of the greatest challenges in the management of this disease. Most patients have multiple tumours in their prostate at the time of diagnosis. This is a complicating factor for developing biomarkers to aid in management of the disease.
The research projects primarily utilise a biobank with multiple frozen tissue cores from each of altogether 571 prostate cancer patients. The biobanking prodedure enables high-quality genomics analyses of multifocal primary prostate cancer, including analyses of interfocal heterogeneity of both gene mutations and gene expression (at gene level, alternative and aberrant splicing, and fusion genes).
Carm KT, Hoff AM, Bakken AC, Axcrona U, Axcrona K, Lothe RA, Skotheim RI*, and Løvf M (2019). The clinical usefulness of molecular classification of primary prostate cancer is challenged by interfocal heterogeneity. Scientific Reports 9: 13579 *Corresponding author
Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, and Skotheim RI (2019). Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. European Urology, 75(3): 498-505
Zhao S, Løvf M, Carm KT, Bakken AC, Hoff AM, and Skotheim RI (2017). Novel transcription-induced fusion RNAs in prostate cancer. Oncotarget 8(30): 49133-43
Barros-Silva JD, Paulo P, Bakken AC, Cerveira N, Løvf M, Henrique R, Jerónimo C, Lothe RA, Skotheim RI, and Teixeira MR (2013). Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer. Neoplasia 15(7): 720-726
Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, and Teixeira MR (2012). Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 14(7): 600-611
Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jerónimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, and Teixeira MR (2012). FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes. Cancer 51(3): 240-249
Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, and Kallioniemi O (2006). TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66(21): 10242-10246